Product Description:

• UBRELVY®is indicated for the acute treatment of migraine with or without aura in adults.


• UBRELVY is not indicated for the preventive treatment of migraine.

How to use:

• The recommended dose of One Tablet UBRELVY is 100 mg taken orally (when needed) with or without food.


• If needed, a second dose may be taken at least 2 hours after the initial dose.


• The maximum dose in a 24-hour period is 200 mg.

Caution & Warnings:

• Hypersensitivity Reactions Hypersensitivity reactions, including anaphylaxis, dyspnea, facial or throat edema, rash, urticaria, and pruritus, have been reported with use of UBRELVY. 3 Hypersensitivity reactions can occur minutes, hours, or days after administration.


• Most reactions occurred within hours after dosing and were not serious, and some reactions led to discontinuation.


• If a serious or severe hypersensitivity reaction occurs, discontinue UBRELVY and institute appropriate therapy

Ingredients:

• Each tablet contains 100 mg of ubrogepant


• The inactive ingredients include colloidal silicon dioxide, croscarmellose sodium, mannitol, microcrystalline cellulose, polyvinylpyrrolidone vinyl acetate copolymer, sodium chloride, sodium stearyl fumarate, and vitamin E polyethylene glycol succinate.